ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 3241 • 2016 ACR/ARHP Annual Meeting

    Genetic Variation and Tobacco Smoke Exposure in Systemic Lupus Erythematosus: A Case Control Study Among African Americans

    Bethany Wolf1, Paula S. Ramos2, Paul Nietert3, J. Madison Hyer1, Viswanathan Ramakrishnan1, Gary S. Gilkeson4, Gerard Hardiman2 and Diane L. Kamen5, 1Public Health Sciences, Medical University of South Carolina, Charleston, SC, 2Medicine, Medical University of South Carolina, Charleston, SC, 3Public Health Science, Medical University of South Carolina, Charleston, SC, 4Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 5Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects African Americans, and the development of SLE is believed to be triggered by exposure to one or more…
  • Abstract Number: 3242 • 2016 ACR/ARHP Annual Meeting

    Identification and Functional Characterization of TNIP1 Causal Variants Associated with Systemic Lupus Erythematosus

    Satish Pasula1, Mandi Wiley1, Ying-yu Wu1, Ajay Nair1, Jaanam Gopalakrishnan2 and Patrick M. Gaffney1, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production and dysregulated interferon responses. Genome-wide association studies (GWAS) have identified more…
  • Abstract Number: 3243 • 2016 ACR/ARHP Annual Meeting

    Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity

    Doua F. Azzouz1, Lelise Getu2, Celine Anquetil1, Jill P. Buyon3 and Gregg J. Silverman3, 1Medicine, NYU School of Medicine, New York, NY, 2Department of Medicine, New York University School of Medicine, New York, NY, 3Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: SLE is a complex multifactorial systemic autoimmune disease, which has been attributed to poorly understood interactions between genetic and environmental factors. Recent reports have…
  • Abstract Number: 3244 • 2016 ACR/ARHP Annual Meeting

    Observations of Early and Late B Cell Alterations during Belimumab Treatment in Patients with Systemic Lupus Erythematosus Using Mass Cytometry (CyTOF)

    Ioannis Parodis1, Daniel Ramsköld1, Petter Brodin2, Agneta Zickert1, Lakshmikanth Tadepally2, Yang Chen2, Jaromir Mikes2, Adnane Achour2, Iva Gunnarsson1 and Vivianne Malmström1, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 2Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose:  Belimumab is a recombinant monoclonal antibody that inhibits soluble B lymphocyte stimulator (BLyS), also known as BAFF or TNFSF13B, and is approved for treating…
  • Abstract Number: 3245 • 2016 ACR/ARHP Annual Meeting

    Surfactant Protein D and Krebs Von Den Lungen-6 Predict Severity of Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts

    Elizabeth R. Volkmann1, Donald P. Tashkin2, Faye N. Hant3, Galina S. Bogatkevich4, Michael Roth5, Kim Hyun6, Jonathan Goldin1, Tanjina Akter7, Holly Wilhalme1, Chi-hong Tseng5, Shervin Assassi8, Dinesh Khanna9, Philip J. Clements5, Daniel E. Furst1, Robert Elashoff10 and Richard Silver11, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 3Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 5Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 6Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 7Department of Rheumatology, Medical University of South Carolina, Charleston, SC, 8Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 9University of Michigan, Ann Arbor, MI, 10Biomathematics, University of California, Los Angeles, Los Angeles, CA, 11Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: A prior study of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) demonstrated that serum concentrations of surfactant protein D (SP-D) and Krebs von…
  • Abstract Number: 3246 • 2016 ACR/ARHP Annual Meeting

    Predictors of Long-Term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

    Kathleen Kolstad1, Shufeng Li2, Virginia D. Steen3 and Lorinda Chung4, 1Rheumatology, Stanford Univeristy, Stanford, CA, 2Dermatology, Stanford University, Stanford, CA, 3Rheumatology, Georgetown University Medical Center, Washington, DC, 4Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose:  Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Predictors of short-term mortality include male sex, age>60…
  • Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting

    Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial

    Jessica K. Gordon1, Eliza Pelrine2, Yuo-Yu Lee3, Cynthia Magro4, Elana J. Bernstein5, Horatio F. Wildman6 and Robert F. Spiera1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 4Pathology, Weill Cornell Medical College, New York, NY, 5Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, 6Dermatology, Weill Cornell Medical College, New York, NY

    Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…
  • Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting

    Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II

    Rajaie Namas1,2, Donald P. Tashkin3, Holly Wilhalme4, Daniel E. Furst5, Chi-hong Tseng6, Michael Roth6, Suzanne Kafaja7, Elizabeth R. Volkmann4, Philip J. Clements6 and Dinesh Khanna8, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, 3David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 4University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5UCLA, Los Angeles, CA, 6Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 7Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 8University of Michigan, Ann Arbor, MI

    Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…
  • Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting

    Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease

    Elizabeth R. Volkmann1, Dinesh Khanna2, Chi-hong Tseng3, Robert Elashoff4, Bingling Wang5, Michael Roth3, Philip J. Clements3, Daniel E. Furst1, Arthur Theodore6 and Donald P. Tashkin7, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of Michigan, Ann Arbor, MI, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Biomathematics, University of California, Los Angeles, Los Angeles, CA, 5Biostatistics, University of California, Los Angeles, Los Angeles, CA, 6Medicine, Boston University, Boston, MA, 7David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
  • Abstract Number: 3250 • 2016 ACR/ARHP Annual Meeting

    Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis

    Minghua Wu1, Murray Baron2, Marie Hudson3, Marvin J. Fritzler4, Claudia Pedroza5, Jun Ying1, Gloria Salazar1, Julio Charles6, Maureen D Mayes1 and Shervin Assassi1, 1Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 2Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, 3Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 4Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 5Pediatrics, University of Texas-McGovern Medical School, Houston, TX, 6Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX

    Background/Purpose:  Currently available clinical biomarkers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in the context of systemic sclerosis (SSc) A previous…
  • Abstract Number: 3251 • 2016 ACR/ARHP Annual Meeting

    Sleep and Physical Activity: A Nationwide Survey Among People with Rheumatic Disease in Ireland

    Sean McKenna1, Alan Donnelly2, Sandy Fraser3 and Norelee Kennedy1, 1Department of Clinical Therapies, University of Limerick, Ireland, Limerick, Ireland, 2Department of Physical Education and Sports Sciences, University of Limerick, Ireland, Limerick, Ireland, 3Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland

    Background/Purpose:   Sleep is an important aspect in maintaining the body’s circadian rhythm and plays an important role in maintaining health. Disrupted or lower levels…
  • Abstract Number: 3252 • 2016 ACR/ARHP Annual Meeting

    Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis

    Lisa Allyn1, Lisa Zoller1, Catherine L. Backman2,3 and Diane Lacaille4,5, 1The University of British Columbia, Vancouver, BC, Canada, 2Department of Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, 3Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, 4Medicine, University of British Columbia, Vancouver, BC, Canada, 5Arthritis Research Canada, Richmond, BC, Canada

    Background/Purpose:  Work cessation and at-work productivity loss are common and early outcomes of inflammatory arthritis (IA). Ergonomic accommodations contribute to successful management of arthritis symptoms…
  • Abstract Number: 3253 • 2016 ACR/ARHP Annual Meeting

    Minimum Physical Function Needed to Walk 6000 Steps/Day in People with Knee Osteoarthritis

    Hiral Master1, Louise Thoma1, Meredith Christiansen1, Emily Polakowski1, Laura Schmitt1 and Daniel White2, 1Physical Therapy and Biomechanics and Movement Science, University of Delaware, Newark, DE, 2Department of Physical Therapy, University of Delaware, Newark, DE

    Title: Minimum Physical Function Needed To Walk 6000 steps/day In People With Knee Osteoarthritis. Background/Purpose: Adopting a physically active lifestyle provides major health benefits to…
  • Abstract Number: 3254 • 2016 ACR/ARHP Annual Meeting

    Use of the Short Valued Life Activities Scale in People with Systemic Sclerosis

    Janet L. Poole1 and Betty Skipper2,3, 1Health Sciences Ctr OT Program, 1 University of New Mexico, Albuquerque, NM, 2Family and Community Medicine, University of New Mexico, Albuquerque, NM, 3Family and Community Medicine, University of New Mexico, University of New Mexico, Albuquerque, NM

    Background/Purpose:   Systemic sclerosis is a chronic autoimmune connective tissue disorder that results in skin thickening, vascular insufficiency, and fibrosis of internal organs, such as…
  • Abstract Number: 3255 • 2016 ACR/ARHP Annual Meeting

    A Randomized Trial of Automated Telephone-Linked Communication to Improve Exercise Adherence for a Progressive Resistance Training Program in People with Knee Osteoarthritis

    Kristin Baker1, Aileen Ledingham1, Carrie Brown2, Kelly Pesanelli3, Faye Cochrane4, Robert Friedman5, Michael P. LaValley6, David T. Felson7 and Julie J. Keysor1,8, 1Physical Therapy, Boston University Sargent College, Boston, MA, 2Boston University School of Public Health, Boston, MA, 3Health Sciences, Boston University Sargent College, Boston, MA, 4ENACT, Boston University Sargent College, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6Biostatistics, Boston University School of Public Health, Boston, MA, 7Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 8Clinical Epidemiology Research and Training, Boston University School of Medicine, Boston, MA

    Background/Purpose: In knee osteoarthritis (OA) strengthening exercise improves pain and physical function, however a marked decline in exercise adherence has limited the long term efficacy…
  • « Previous Page
  • 1
  • …
  • 1631
  • 1632
  • 1633
  • 1634
  • 1635
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology